Does Semaglutide Affect Your Mood and Mental Wellbeing?

What the safety reviews actually found

When reports of suicidal thoughts linked to GLP-1 medicines began surfacing in European pharmacovigilance databases in 2023, regulators moved quickly. The MHRA participated in a Europe-wide review and published its conclusions: based on the data available, a causal relationship between semaglutide and suicidal ideation or self-harm had not been established. That is reassuring, but it is not a clean all-clear, the medicines are still under additional monitoring (you will see the black triangle ▼ on Wegovy packaging), and any new reports continue to feed into the ongoing assessment.

What the NHS medicines page for semaglutide does list as known side effects include depression and mood changes, classified as uncommon. That classification means the clinical trials detected them in a meaningful fraction of participants, not rare enough to dismiss, not common enough to expect. It is the kind of honest, mid-range signal that deserves attention rather than either alarm or dismissal.

One practical habit worth forming: each week, before you take your injection, spend sixty seconds doing a quick mental check. Note whether your sleep, motivation or general emotional tone has shifted since the last dose. Jotting this in your phone takes under a minute and gives you something concrete to share at your next clinical review, rather than relying on a vague sense that something feels different.

Why mood might improve, and why that matters for your decision

The conversation about semaglutide and mood is not one-sided. In the STEP 1 trial, participants using semaglutide reported meaningful improvements in health-related quality of life alongside weight reduction, and mood is part of that picture. Carrying significant excess weight is associated with higher rates of depression, social withdrawal and reduced self-esteem, so as physical health improves, emotional wellbeing sometimes follows. That effect is real and documented, even if it is not universal.

This is where the decision frame matters. You are not simply deciding whether semaglutide might lower your mood; you are weighing that possibility against your current situation, which for many people already includes low mood tied to weight and health. Neither calculation is straightforward. The broader side-effect profile of semaglutide involves mostly gastrointestinal symptoms, which tend to be front-loaded and then settle, the mood question is a separate thread worth exploring with your prescriber rather than resolving alone.

People who have a personal or family history of depression, bipolar disorder or eating disorders will want a particularly thorough conversation before starting. That is not a reason to rule treatment out automatically; it is a reason to make sure a real clinician, not a form, has taken that history seriously.

Does Wegovy specifically carry a different risk profile for mood?

Wegovy is the weight-management brand of semaglutide, and if you want to understand in more detail how Wegovy can affect your mood, the mood-related signals in the literature come from its trial programme and post-marketing data for this indication. Questions about Wegovy and mood often conflate it with Ozempic, the diabetes version of the same molecule, both contain semaglutide, but the licensed populations, doses and monitoring contexts differ. Wegovy reaches 2.4mg over roughly five months of dose escalation; prescribers consider mental health history at each clinical review, not just at the start.

The MHRA advises that anyone experiencing new or worsening depression, anxiety, or thoughts of harming themselves while using any GLP-1 medicine should seek medical help promptly. That advice does not suggest the medicines routinely cause these problems, it reflects responsible pharmacovigilance. If you want to compare the full side-effect considerations for Wegovy before making a decision, that detail is laid out separately.

What a clinical review at nume covers on this topic

Every consultation at nume is personally read by a GPhC-registered Independent Prescriber, not processed by software. Mental health history is part of that assessment. If you are currently being treated for depression or anxiety, or have been in the past, your prescriber will consider whether semaglutide is appropriate, whether any adjustments to monitoring are sensible, and what to watch for. If a question arises mid-treatment, our aftercare team is available seven days a week.

For anyone considering Wegovy for weight management, the mood question is worth raising directly in your consultation rather than worrying about it quietly, and if you are also navigating questions about whether semaglutide is safe while breastfeeding, that too deserves an open conversation with your prescriber rather than a quiet assumption either way. A prescriber who knows your history gives you a far better answer than any article can. That said, if you are in distress now, the right first step is your GP or NHS 111, not a weight-loss consultation.

If you are ready to have that conversation, you can start your free consultation and a prescriber will review your answers the same day.